An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...

SINGAPORE – Ketamine, the controlled drug best known ... first authorized sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients ...

SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best ... first authorised sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy ...

Ketamine, the controlled drug best known as a horse tranquilliser ... Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious ...

SINGAPORE – Ketamine, the controlled drug best known as a horse tranquilliser ... Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

most studies of ketamine in depression have relied on either intravenous or intranasal administration, the latter resulting in the approval of J&J’s Spravato (esketamine) for TRD in 2019 and for ...